Abstract Details

Title IV Administration of AAV5-IGF Improves Weakness of Heterozygous [italic]Mpz [/italic]mice, the Animal Model of Late onset CMT1B

Topic Neurogenetics and Gene Therapy

Presentation(s) (-)

Poster/Presentation
Number 002

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
	No disclosure on file
Emilia Ianakova, MD	No disclosure on file
	No disclosure on file
Gyula Acsadi, MD, FAAN (Connecticut Children'S Medical Center/UConn)	Dr. Acsadi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Acsadi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avexis. Dr. Acsadi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Serepta. Dr. Acsadi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Acsadi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Michael E. Shy, MD, FAAN (University of Iowa)	Dr. Shy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Therapeutics. The institution of Dr. Shy has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for DTx Pharma. The institution of Dr. Shy has received research support from NIH. The institution of Dr. Shy has received research support from Muscular Dystrophy Association. The institution of Dr. Shy has received research support from Charcot Marie Tooth Association. The institution of Dr. Shy has received research support from Applied Therapeutics.
	No disclosure on file

��ɫ��